# PMN310 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/pmn310

> The next catalyst for PMN310, sponsored by ProMIS Neurosciences Inc. (PMN), is its topline data readout, Q1 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: half-year only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What is the next FDA catalyst for PMN310?

The next catalyst for PMN310, sponsored by ProMIS Neurosciences Inc. (PMN), is its topline data readout, Q1 2027. SEC Form 10-Q: "On July 28, 2026, reported positive blinded six-month interim safety and biomarker results from the PRECISE-AD Phase 1b study of PMN310, showing no ARIA-E across all genotypes in a population that included 61% APOE4 carriers (of which 11% were homozygotes), ARIA-H of 4.4% (all mild and asymptomatic), no treatment-related SAEs and no drug-related discontinuations, and early biomarker movement consistent with target engagement; unblinded 12-month topline data are expected in the first quarter of 2027." [Calendar and source filings](https://sec-api.dev/pdufa/pmn310)

Source: SEC Form 10-Q, accession 0001104659-26-126263, https://www.sec.gov/Archives/edgar/data/1374339/000110465926126263/pmn-20260930x10q.htm (retrieved 2026-11-13). Last confirmed 2026-11-12. Cite: https://sec-api.dev/pdufa/pmn310#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | PMN310 |
| Codes | PMN310 |
| Sponsor | ProMIS Neurosciences Inc. (PMN) https://sec-api.dev/companies/pmn/catalysts |
| Indications | early ad, [alzheimer's disease](https://sec-api.dev/indications/alzheimer-s-disease) |
| Modality |  |
| FDA designations | fast track |

## Timeline

### late 2024: trial start

- Status: scheduled. Date confidence: half. Stage: 1. Indication: Alzheimer's disease.
- First seen 2024-11-14, last confirmed 2024-11-14.
- Press release filed with the SEC (EX-99) (accession 0001558370-24-015632): "On track to initiate Phase 1b clinical trial in patients with Alzheimer's disease by end of 2024" https://www.sec.gov/Archives/edgar/data/1374339/000155837024015632/pmn-20241114xex99d1.htm

### December 31, 2024: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2025-03-31, last confirmed 2026-11-12.
- SEC Form 10-K (accession 0001558370-25-004068): "This increase is primarily attributable to a $3.5 million increase in spending on our lead program, PMN310, as we completed our Phase 1a clinical trial of PMN310 and initiated the Phase 1b clinical trial of PMN310 during the year ended December 31, 2024." https://www.sec.gov/Archives/edgar/data/1374339/000155837025004068/pmn-20241231x10k.htm
- SEC Form 10-Q (accession 0001104659-26-126263): "We successfully completed our single ascending dose (SAD) Phase 1a clinical trial with PMN310 and commenced our Phase 1b clinical trial ("PRECISE-AD") in December 2024." https://www.sec.gov/Archives/edgar/data/1374339/000110465926126263/pmn-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095895): "We successfully completed our single ascending dose (SAD) Phase 1a clinical trial with PMN310 and commenced our Phase 1b clinical trial ("PRECISE-AD") in December 2024." https://www.sec.gov/Archives/edgar/data/1374339/000110465926095895/pmn-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-059035): "We successfully completed our Phase 1a clinical trial with PMN310 and commenced our Phase 1b clinical trial ("PRECISE-AD") in December 2024." https://www.sec.gov/Archives/edgar/data/1374339/000110465926059035/pmn-20260331x10q.htm
- SEC Form 10-Q (accession 0001104659-25-109719): "We successfully completed our Phase 1a clinical trial with PMN310 and commenced our Phase 1b clinical trial ("PRECISE-AD") in December 2024." https://www.sec.gov/Archives/edgar/data/1374339/000110465925109719/pmn-20250930x10q.htm
- SEC Form 10-Q (accession 0001558370-25-011299): "We successfully completed our Phase 1a clinical trial with PMN310 and commenced our Phase 1b clinical trial ("PRECISE-AD") in December 2024." https://www.sec.gov/Archives/edgar/data/1374339/000155837025011299/pmn-20250630x10q.htm
- SEC Form 10-Q (accession 0001558370-25-007255): "We successfully completed our Phase 1a clinical trial with PMN310 and commenced our Phase 1b clinical trial ("PRECISE-AD") in December 2024." https://www.sec.gov/Archives/edgar/data/1374339/000155837025007255/pmn-20250331x10q.htm

### mid-2026: topline data readout

- Status: scheduled. Date confidence: half.
- First seen 2026-01-30, last confirmed 2026-01-30.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-008325): "We believe we remain on track to report blinded top-line data in mid-2026 and 12-month top-line data toward the end of 2026."" https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/pmn-20260129xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-008325): "Blinded 6-month top-line data expected mid-2026; 12-month top-line data expected toward end of 2026" https://www.sec.gov/Archives/edgar/data/1374339/000110465926008325/pmn-20260129xex99d1.htm

### Q2 2026: interim data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-01-10, last confirmed 2026-03-25.
- Press release filed with the SEC (EX-99) (accession 0001558370-25-007253): ""We view the planned interim analysis in the first half of 2026 as an important opportunity to generate early insights into PMN310's potential to drive both clinical benefit and improved tolerability, particularly with respect to reducing or avoiding ARIA, a key differentiator in this space." https://www.sec.gov/Archives/edgar/data/1374339/000155837025007253/pmn-20250512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-109714): "On track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026" https://www.sec.gov/Archives/edgar/data/1374339/000110465925109714/pmn-20251112xex99d1.htm
- SEC Form 8-K (accession 0001558370-25-011845): "Enrollment of patients into Cohort 3 is now underway, keeping the Company on track to deliver 6-month interim data in the second quarter of 2026 and final top-line results in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1374339/000155837025011845/pmn-20250903x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011845): "Enrollment of patients into Cohort 3 is now underway, keeping the Company on track to deliver 6-month interim data in the second quarter of 2026 and final 12-month top-line results in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1374339/000155837025011845/pmn-20250903xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011297): "At this stage, we remain on track to deliver 6-month blinded interim results in 2Q 2026 and final topline results in 4Q 2026."" https://www.sec.gov/Archives/edgar/data/1374339/000155837025011297/pmn-20250813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011845): "The trial, expected to enroll 128 patients, remains on track to report 6-month interim data in Q2 2026 and final 12-month top-line results in Q4 2026." https://www.sec.gov/Archives/edgar/data/1374339/000155837025011845/pmn-20250903xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011297): "ProMIS expects to report blinded six-month interim results from PRECISE-AD in 2Q 2026, with topline results anticipated in 4Q 2026." https://www.sec.gov/Archives/edgar/data/1374339/000155837025011297/pmn-20250813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-004070): "PRECISE-AD Six Month Interim Results Expected in 1H 2026 with Topline Results Anticipated by end of 2026" https://www.sec.gov/Archives/edgar/data/1374339/000155837025004070/pmn-20250331xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-004070): "ProMIS expects to report six-month interim results from PRECISE-AD in the first half of 2026, with topline results anticipated by the end of 2026." https://www.sec.gov/Archives/edgar/data/1374339/000155837025004070/pmn-20250331xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-001435): "Six-month Interim Results Expected in 1H 2026 with Topline Results Anticipated in 2H 2026" https://www.sec.gov/Archives/edgar/data/1374339/000155837025001435/pmn-20250225xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-004070): "With strong enthusiasm from investigators and patients, we are pleased with the study's momentum and remain on track to deliver interim data in 2026, which we believe could validate PMN310 as a potential best-in-class treatment for AD." https://www.sec.gov/Archives/edgar/data/1374339/000155837025004070/pmn-20250331xex99d1.htm
- SEC Form 10-Q (accession 0001104659-25-109719): "We anticipate reporting six-month interim data from the study in the second quarter of 2026, with topline results expected in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1374339/000110465925109719/pmn-20250930x10q.htm

### Q3 2026: interim data readout

- Status: scheduled. Date confidence: quarter. Stage: 1.
- First seen 2025-09-03, last confirmed 2026-05-12.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058967): "Near-term data catalysts, including the blinded 6-month interim analysis, are anticipated in early Q3 2026, and could provide important insight into the potential of our lead drug candidate, PMN310." https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-034162): "Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027" https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/pmn-20260325xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058967): "Interim Data Readout: Blinded interim analysis of PRECISE-AD safety and biomarker data anticipated early Q3 2026." https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058967): "The upcoming blinded interim data analysis anticipated in early Q3 2026 will summarize aggregate safety data and overall trends in key biomarkers across all study participants, without revealing treatment assignments." https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058967): "A blinded interim analysis is anticipated in early third quarter 2026, providing a mid-study review of aggregated safety data and overall biomarker trends across all participants." https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-034162): "The blinded interim analysis is anticipated in early third quarter 2026." https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/pmn-20260325xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-034162): "Six-month blinded interim data expected early third quarter 2026." https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/pmn-20260325xex99d1.htm
- SEC Form 10-Q (accession 0001104659-26-059035): "Based on current clinical trial patient visit schedules, we expect to complete the six-month assessments in the second quarter of 2026, with the blinded interim analysis anticipated in early third quarter 2026." https://www.sec.gov/Archives/edgar/data/1374339/000110465926059035/pmn-20260331x10q.htm
- SEC Form 10-K (accession 0001104659-26-034554): "Based on current clinical trial patient visit schedules, the Company expects to complete the six-month assessments in the second quarter of 2026, with the blinded interim analysis anticipated in early third quarter 2026." https://www.sec.gov/Archives/edgar/data/1374339/000110465926034554/pmn-20251231x10k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058967): "PRECISE-AD Phase 1b trial is fully enrolled and progressing on schedule, with the blinded 6-month interim analysis anticipated in early Q3 2026 and 12-month top-line data anticipated in early 2027." https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001558370-25-011845): ""The DSMB's recommendation to proceed with the planned escalation to the final dose cohort underscores the steady progress of our Phase 1b program and keeps us firmly on track toward our planned interim and top-line data readouts in 2026," said Neil Warma, President and CEO of ProMIS Neurosciences." https://www.sec.gov/Archives/edgar/data/1374339/000155837025011845/pmn-20250903xex99d1.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 1. Indication: early AD.
- First seen 2026-03-25, last confirmed 2026-11-12.
- SEC Form 10-Q (accession 0001104659-26-126263): "On July 28, 2026, reported positive blinded six-month interim safety and biomarker results from the PRECISE-AD Phase 1b study of PMN310, showing no ARIA-E across all genotypes in a population that included 61% APOE4 carriers (of which 11% were homozygotes), ARIA-H of 4.4% (all mild and asymptomatic), no treatment-related SAEs and no drug-related discontinuations, and early biomarker movement consistent with target engagement; unblinded 12-month topline data are expected in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1374339/000110465926126263/pmn-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-095895): "Hosted a webinar reporting positive blinded six-month interim safety and biomarker results from the PRECISE-AD Phase 1b study of PMN310, showing no ARIA-E across all genotypes in a population that included 61% APOE4 carriers (of which 11% were homozygotes), total ARIA of 4.4% (all mild and asymptomatic ARIA-H), no treatment-related serious adverse events and no drug-related discontinuations, and early biomarker movement consistent with target engagement; unblinded 12-month topline data are expected in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1374339/000110465926095895/pmn-20260630x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-126260): "PRECISE-AD Phase 1b clinical trial in Alzheimer's patients remains on track for unblinded 12-month topline data in the first quarter of 2027, including full safety, biomarker and cognitive outcomes data" https://www.sec.gov/Archives/edgar/data/1374339/000110465926126260/pmn-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095905): "We look forward to the 12-month unblinded topline results from PRECISE-AD, expected in the first quarter of 2027, which will include cognitive outcomes, and we believe will represent an important next step in evaluating PMN310's potential for patients with early AD."" https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/pmn-20260813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-058967): "ProMIS expects to complete 12-month dosing for all patients by year-end and to report unblinded top-line results in early 2027, providing a comprehensive view of PMN310's safety, biomarker, and clinical outcomes by treatment group, and an important clinical test of PMN310's selective targeting approach."" https://www.sec.gov/Archives/edgar/data/1374339/000110465926058967/pmn-20260512xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-126260): ""With PRECISE-AD closing out its final stage of patient visits, we look forward to reporting topline data in the first quarter of 2027, which will include safety, biomarker and clinical efficacy measures." https://www.sec.gov/Archives/edgar/data/1374339/000110465926126260/pmn-ex99d1.htm
- SEC Form 8-K (accession 0001104659-26-087269): "The trial remains blinded and ongoing with topline 12-month results expected in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1374339/000110465926087269/pmn-20260728x8k.htm
- SEC Form 8-K (accession 0001104659-26-087269): "Clear path forward: Unblinded 12-month topline data expected Q1 2027, including efficacy data." https://www.sec.gov/Archives/edgar/data/1374339/000110465926087269/pmn-20260728x8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-087269): "We look forward to our 12-month topline readout in the first quarter of 2027."" https://www.sec.gov/Archives/edgar/data/1374339/000110465926087269/pmn-20260728xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-126260): "Presentation of unblinded 12-month topline data from PRECISE-AD, anticipated in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1374339/000110465926126260/pmn-ex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095905): "The Company expects all patients to complete 12-month dosing by the fourth quarter of 2026 and, following database lock and statistical analysis, to report unblinded 12-month topline data, including the full safety dataset, an expanded biomarker panel, and clinical cognitive outcome measures, in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/pmn-20260813xex99d1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-095905): "Presentation of unblinded 12-month topline data from PRECISE-AD, anticipated in the first quarter of 2027." https://www.sec.gov/Archives/edgar/data/1374339/000110465926095905/pmn-20260813xex99d1.htm

## Same indication

- [ACI-24](https://sec-api.dev/pdufa/aci-24) (ACIU)
- [Sabirnetug](https://sec-api.dev/pdufa/sabirnetug) (ABOS)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/pmn310.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PMN310 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/pmn310

```bibtex
@misc{secapidev_pdufa_pmn310_20261116,
  title        = {PMN310 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/pmn310}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_pmn310_20261116","title":"PMN310 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/pmn310","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
